Brief: Seelos Therapeutics Announces Data Demonstrating Significant Downregulation Of Mrna And Reduction Of Alpha Synuclein In An In Vitro Gene Therapy Study
09/06/2022 13:17
June 9 (Reuters) - Seelos Therapeutics Inc SEEL.O :
* SEELOS THERAPEUTICS ANNOUNCES DATA DEMONSTRATING
STATISTICALLY
SIGNIFICANT DOWNREGULATION OF MRNA AND REDUCTION OF ALPHA
SYNUCLEIN IN AN IN VITRO GENE THERAPY STUDY OF SLS-004 UTILIZING
CRISPR-DCAS9 IN DEMENTIA WITH LEWY BODIES
* SEELOS THERAPEUTICS - SINGLE DOSE OF SLS-004 PRODUCED 19%
DOWNREGULATION OF MRNA AND ABOUT 40% REDUCTION OF
ALPHA-SYNUCLEIN COMPARED TO CONTROL GROUP
* SEELOS THERAPEUTICS INC- PLANS TO ADVANCE STUDY OF SLS-004
IN
DLB IN ADDITIONAL PRECLINICAL STUDIES
Source text for Eikon: ID:nPn6KccY7a
Further company coverage: SEEL.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Seelos Therapeutics
See all newsBrief: Seelos Therapeutics Commences Chapter 11 Proceedings- Court Filing
Brief: Seelos Therapeutics Announces Notice Of Delisting From Nasdaq And Transfer Of Listing To Over-The-Counter Market
Brief: Seelos Announces Postponement Of Its Annual Meeting Of Stockholders
Brief: Seelos Therapeutics Announces 1-For-16 Reverse Stock Split
U.S. STOCKS ON THE MOVE-Copper miners, Visa, Bluebird bio